ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Sold by Jane Street Group LLC

Jane Street Group LLC reduced its position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 29.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 101,224 shares of the company's stock after selling 42,851 shares during the period. Jane Street Group LLC owned approximately 0.37% of ClearPoint Neuro worth $1,135,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in CLPT. Verition Fund Management LLC purchased a new position in shares of ClearPoint Neuro during the 3rd quarter worth approximately $123,000. Pekin Hardy Strauss Inc. purchased a new position in ClearPoint Neuro in the third quarter worth $541,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in ClearPoint Neuro in the third quarter valued at $366,000. Oppenheimer & Co. Inc. purchased a new stake in shares of ClearPoint Neuro during the 3rd quarter worth $156,000. Finally, Essex Investment Management Co. LLC grew its stake in shares of ClearPoint Neuro by 0.3% during the 3rd quarter. Essex Investment Management Co. LLC now owns 463,853 shares of the company's stock worth $5,200,000 after purchasing an additional 1,267 shares during the period. Institutional investors and hedge funds own 30.08% of the company's stock.

ClearPoint Neuro Trading Down 1.7 %

Shares of CLPT traded down $0.26 during trading hours on Monday, reaching $15.49. The company had a trading volume of 160,354 shares, compared to its average volume of 192,367. The company has a market capitalization of $427.29 million, a price-to-earnings ratio of -22.45 and a beta of 1.08. ClearPoint Neuro, Inc. has a 12-month low of $5.11 and a 12-month high of $17.47. The firm has a 50 day simple moving average of $13.25 and a 200-day simple moving average of $10.73.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.